UTIs and two new antibiotics in the elderly

Area of Science:

• Pharmacology
• Infectious Diseases
• Urology

Background:

• Urinary tract infections (UTIs) require effective antimicrobial therapy.
• New beta-lactam antibiotics, aztreonam and imipenem/cilastatin, offer distinct treatment options.
• Understanding their specific antimicrobial spectra is crucial for optimal UTI management.

Purpose of the Study:

• To compare the efficacy and tolerability of aztreonam and imipenem/cilastatin for treating UTIs.
• To delineate the distinct antimicrobial spectrums of aztreonam and imipenem/cilastatin.
• To guide the appropriate use of these novel beta-lactam antibiotics in clinical practice.

Main Methods:

• Review of comparative clinical trials involving aztreonam and imipenem/cilastatin in patients with complicated UTIs.
• Analysis of antimicrobial spectrum data for both agents against common UTI pathogens.
• Evaluation of tolerability and efficacy data from clinical studies.

Main Results:

• Aztreonam demonstrates a directed spectrum against gram-negative bacilli typically causing UTIs.
• In complicated UTI trials, aztreonam showed comparable efficacy and good tolerability to aminoglycoside regimens.
• Imipenem/cilastatin possesses a broad spectrum, encompassing gram-negative bacilli, gram-positive cocci, and anaerobes.

Conclusions:

• Aztreonam is a well-tolerated and effective option for UTIs caused by susceptible gram-negative organisms.
• Imipenem/cilastatin's broad-spectrum activity makes it suitable for treating mixed bacterial infections.
• The distinct antimicrobial profiles necessitate careful selection based on the suspected or confirmed pathogens in UTIs.